Bayer Demonstrates New Suite of Digital Radiology AI-Enabled Applications at ECR 2022

By MedImaging International staff writers
Posted on 12 Jul 2022

Image: Calantic Digital Solutions delivers access to AI-enabled programs for medical imaging (Photo courtesy of Bayer)

Bayer (Leverkusen, Germany) demonstrated its recently-launched suite of digital radiology AI-enabled applications at the on-site European Congress of Radiology (ECR) in Vienna. Bayer has launched its new platform at a time when chronic diseases are on the rise, increasing the demand for medical imaging. With radiology’s increasing complexity, including a five-fold jump in the number of magnetic resonance imaging (MRI) images produced per scan, to meet workload demands, an average radiologist in some cases would need to interpret one image every three-four seconds in an eight-hour workday. Exacerbating this situation is a shortage of radiologists. Time pressure and workload contribute to the prevalence of burn-out among radiologists. In addition, data show the rate of diagnostic errors rises with long hours of overtime. Digital technologies can help manage the mounting workload of radiologists and their teams, ultimately striving to improve patient care.

At ECR 2022, Bayer demonstrated its Calantic Digital Solutions – the company’s new platform delivering access to digital applications, including artificial intelligence (AI) enabled programs for medical imaging. Calantic Digital Solutions is a suite of digital radiology AI-enabled applications which assist radiologists and their teams at critical steps within a patient’s treatment journey. The vendor-neutral, cloud-hosted platform includes a growing number of applications designed to aid in prioritization, lesion detection and quantification, as well as apps that automate routine tasks and measurements, improve the radiology suites’ workflow, and free up time for radiologists and their teams. The offering is orchestrated by body region and procedure, initially focusing on thoracic and neurological diseases, such as pulmonary nodule detection and triage of potential intracerebral hemorrhage (ICH) and large vessel occlusions (LVO). ICH and LVO can be associated with stroke. More disease-specific application packages will be added moving forward.

“As a leader in key Radiology areas and building on our deep medical understanding across a multitude of diagnostic and therapeutic areas, Calantic Digital Solutions underlines our commitment to continue accelerating innovation for the benefit of patients and their physicians”, said Gerd Krueger, Head of Radiology, Bayer Pharmaceuticals. “With Calantic Digital Solutions, we are entering the fastest growing segment in the radiology market and taking the next step on our way from a product provider to a solution provider, following our mission to provide an ecosystem of third-party and Bayer products to deliver state-of-the art disease-oriented solutions for radiologists and their teams.”

Related Links:
Bayer